- Home
- MRCC vs ACRS Comparison
MRCC vs ACRS Comparison
Compare MRCC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | ACRS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 230.8M |
| IPO Year | 2012 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MRCC | ACRS |
|---|---|---|
| Price | $6.50 | $3.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $8.00 | ★ $9.75 |
| AVG Volume (30 Days) | 89.6K | ★ 1.4M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 11.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,742,000.00 | $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.86 | $1.05 |
| 52 Week High | $8.85 | $3.48 |
Technical Indicators
Market Signals| Indicator | MRCC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 58.43 |
| Support Level | $6.20 | $3.12 |
| Resistance Level | $6.80 | $3.48 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 52.54 | 59.32 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.